IVBXF Overview

Clinical Trial Success: Innovent Biologics' Phase 1b trial of mazdutide injection in Chinese adolescents with obesity met its primary endpoint, showing significant BMI and weight reductions compared to placebo.

Study Details: The trial involved 36 adolescents aged 12-18 who had not achieved sufficient weight loss through diet and exercise, with the mazdutide groups achieving BMI reductions of 8.78% and 10.99%.

Safety Profile: Mazdutide demonstrated a favorable safety and tolerability profile, with no serious adverse events reported and only mild to moderate gastrointestinal side effects observed.

Future Plans: Innovent plans to initiate a Phase 3 trial to further evaluate mazdutide, addressing the urgent need for effective obesity treatments in adolescents, as no weight-loss medications are currently approved for this age group in China.

Study Results: Innovent Biologics' PECONDLE (picankibart injection) met primary and key secondary efficacy endpoints in the Phase 3 CLEAR-2 study for moderate-to-severe plaque psoriasis, showing high maintenance rates of PASI 90 response at Week 56.

Efficacy and Safety: The treatment demonstrated durable efficacy with significant improvements in various psoriasis severity measures and maintained a favorable safety profile without new safety signals.

Treatment Comparison: Patients receiving maintenance treatment with picankibart had significantly better outcomes compared to those who underwent treatment withdrawal, highlighting its disease-modifying potential.

Market Approval: PECONDLE is the first China-developed IL-23p19 monoclonal antibody, receiving market approval from the NMPA in November 2025 for adult patients eligible for systemic therapy.

Innovent's NRDL Inclusion: Innovent Biologics announced that seven of its innovative products, including TYVYT® and SYCUME®, have been included in China's updated National Reimbursement Drug List (NRDL), effective January 1, 2026, enhancing patient access to critical therapies for various diseases.

New Indications and Treatments: The updated NRDL features new indications for TYVYT® in advanced endometrial cancer and SYCUME® for moderate-to-severe thyroid eye disease, addressing significant treatment gaps in these areas.

Innovative Therapies for Cancer: Other newly included therapies in the NRDL include Limertinib for NSCLC with specific mutations, Dupert® for KRAS G12C mutation, DOVBLERON® for ROS1-positive NSCLC, and Retsevmo® for cancers with RET alterations, providing targeted treatment options.

Commitment to Patient Accessibility: Innovent emphasizes its mission to empower patients with affordable, high-quality biopharmaceuticals, continuing to invest in innovative treatments across oncology, cardiovascular, autoimmune, and ophthalmology sectors to improve drug affordability and accessibility.

Collaboration Announcement: Innovent Biologics has finalized a global strategic collaboration with Takeda to enhance the development and commercialization of its immuno-oncology and antibody-drug conjugate therapies, including IBI363 and IBI343.

Co-Development and Commercialization: The agreement allows for co-development of IBI363 in the U.S. with shared manufacturing rights, while Takeda gains exclusive rights for IBI343 and an option for IBI3001 outside Greater China.

Financial Terms: Takeda will make an upfront payment of $1.2 billion to Innovent, which includes a $100 million equity investment, with potential milestone payments bringing the total deal value to approximately $11.4 billion.

Royalty and Profit Sharing: Innovent will receive royalties for each molecule outside Greater China, and profits and losses for IBI363 in the U.S. will be shared on a 40/60 basis between Innovent and Takeda.

Clinical Trial Success: Innovent Biologics announced that its Phase 3 trial of mazdutide, a dual glucagon/GLP-1 receptor agonist, met all primary and key secondary endpoints for weight management in Chinese adults with obesity.

Weight Loss Results: Participants receiving mazdutide 9 mg experienced significant weight loss, achieving a mean reduction of 18.55% at Week 60, with 44% of participants losing 20% or more of their weight, compared to only 3.02% and 2.6% in the placebo group, respectively.

Cardiometabolic Improvements: The study also showed improvements in various cardiometabolic markers, including waist circumference and cholesterol levels, with mazdutide demonstrating superiority over placebo in all measured endpoints.

Safety Profile: Mazdutide 9 mg was well-tolerated, with mild to moderate gastrointestinal adverse events and a low discontinuation rate due to side effects, indicating a favorable safety profile.

Positive Clinical Trial Results: Innovent Biologics announced successful results from its fourth Phase 3 trial, DREAMS-3, for mazdutide, a dual GLP-1 and glucagon receptor agonist, in Chinese patients with type 2 diabetes and obesity.

Efficacy Compared to Semaglutide: At week 32, 48.0% of mazdutide patients achieved significant glycemic control and weight loss, outperforming the 21.0% in the semaglutide group, with notable reductions in HbA1c and body weight.

Safety Profile: The safety of mazdutide was consistent with previous studies, with no new safety concerns identified, and the most common adverse events were mild to moderate gastrointestinal symptoms.

Therapeutic Potential: The findings highlight mazdutide's potential as a next-generation treatment for type 2 diabetes and obesity, demonstrating superior efficacy in glycemic control and weight management compared to existing therapies.